This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy
by Zacks Equity Research
Alexion (ALXN) reports positive data on Ultomiris in adult patients with paroxysmal nocturnal hemoglobinuria.
Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
5 Best-Performing Summer Stocks to Add to Your Watch List
by Tirthankar Chakraborty
We highlight five stocks that tend to do well during summer, the period between the Memorial Day and the Labor Day.
Why Is Alexion (ALXN) Down 6.3% Since Last Earnings Report?
by Zacks Equity Research
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?
by Zacks Equity Research
Alexion (ALXN) gains 30.7% on solid performance of lead drug Soliris and approval of Ultomiris.
3 Reasons Growth Investors Will Love Alexion (ALXN)
by Zacks Equity Research
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
ALXN or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. ALKS: Which Stock Is the Better Value Option?
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.
What Makes Alexion (ALXN) a New Buy Stock
by Zacks Equity Research
Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biotech ETFs in Focus on String of Q1 Earnings Beats
by Sweta Jaiswal, FRM
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week are earnings releases by most leading biotech entities.
Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.
Alexion (ALXN) Tops Q1 Earnings and Revenues Beat Estimates
by Madhu Goel
Alexion (ALXN) beats both earnings and sales estimates in the first quarter of 2019.
Will Biotech ETFs Continue to Rally in Q1 Earnings?
by Sweta Jaiswal, FRM
Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .
Can Alexion (ALXN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion's (ALXN) first-quarter 2019 results are likely to gain on solid performance of lead drug, Soliris. Investors will also focus on updates on pipeline candidates.
Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA
by Zacks Equity Research
Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).
Achillion Meets Enrollment Target in Kidney Disease Studies
by Zacks Equity Research
Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.
Achillion Completes Enrollment in Rare Blood Disorder Study
by Zacks Equity Research
Achillion (ACHN) achieves enrollment target in a mid-stage study evaluating its lead candidate, ACH-4471, in paroxysmal nocturnal hemoglobinuria, a rare life-threatening disease of the blood.
Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL
by Zacks Equity Research
Key highlights of the past week are multiple study failures and other pipeline updates.
Why Is Alexion (ALXN) Up 9.7% Since Last Earnings Report?
by Zacks Equity Research
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.